By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Hormones / antineoplastics > Tamoxifen > Tamoxifen Dosage
Hormones / antineoplastics
https://themeditary.com/dosage-information/tamoxifen-dosage-6806.html

Tamoxifen Dosage

Drug Detail:Tamoxifen (Tamoxifen [ ta-mox-i-fen ])

Drug Class: Hormones / antineoplastics Selective estrogen receptor modulators

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

Usual Adult Dose for Breast Cancer

Metastatic breast cancer in women and men:
20 to 40 mg orally daily for 5 years; doses greater than 20 mg should be given in divided doses (morning and evening)

DCIS following breast surgery and radiation:
20 mg orally daily for 5 years

To reduce the incidence of breast cancer in women at high risk for breast cancer:
20 mg orally daily for 5 years

Comments:

  • There are no data to support the use of this drug other than for 5 years.

Uses:
  • Metastatic For metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, this drug is an alternative to oophorectomy or ovarian irradiation. Patients whose tumors are estrogen receptor positive are more likely to benefit.
  • Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, to reduce the risk of invasive breast cancer.
  • Reduction in Breast Cancer Incidence in High Risk Women: To reduce the incidence of breast cancer in women at high risk. "High risk" is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer greater than or equal to 1.67%, as calculated by the Gail Model.

Usual Adult Dose for Breast Cancer - Adjuvant

20 mg orally once daily or 10 mg orally 2 times daily
Duration of therapy: Up to 5 years

Comments:

  • There are no data to support the use of this drug other than for 5 years.

Use: For the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation

Usual Pediatric Dose for McCune-Albright Syndrome

Girls 2 to 10 years with McCune-Albright Syndrome and precocious puberty:
20 mg orally once daily
Duration of therapy: Up to 12 months

Use: McCune-Albright Syndrome; precocious puberty

Usual Pediatric Dose for Precocious Puberty

Girls 2 to 10 years with McCune-Albright Syndrome and precocious puberty:
20 mg orally once daily
Duration of therapy: Up to 12 months

Use: McCune-Albright Syndrome; precocious puberty

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:
Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer:

  • Serious and life-threatening events associated with this drug in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke, and pulmonary embolism. Uterine malignancies consist of both endometrial adenocarcinoma and uterine sarcoma.
  • Some of the strokes, pulmonary emboli, and uterine malignancies were fatal.
  • Health care providers should discuss the potential benefits versus risks of these events with women at high risk of breast cancer and women with DCIS considering this drug to reduce their risk of developing breast cancer.
  • The benefits of this drug outweigh its risks in women already diagnosed with breast cancer.
CONTRAINDICATIONS:
  • Hypersensitivity to the active component or any of the ingredients
  • In women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep-vein thrombosis or pulmonary embolus

Safety and efficacy have not been established in male patients younger than 18 years.

Safety and efficacy have not been established in female patients younger than 2 years for McCune-Albright Syndrome and precocious puberty, or female patients 10 years to 18 years for McCune-Albright Syndrome and precocious puberty.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Patient advice:

  • Swallow the tablet whole, with water or another non-alcoholic liquid.
  • This drug can be taken with or without food.
  • If a dose is forgotten, take it when you remember, then take the next dose as usual. If it is almost time for your next dose or you remember at your next dose, do not take extra tablets to make up the missed dose.
  • Take this drug for 5 years, unless your doctor tells you otherwise.

Frequently asked questions

  • How do you relieve joint pain associated with tamoxifen or Aromasin?
  • Is it common to lose hair AFTER stopping tamoxifen?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by